INDIANAPOLIS, May 28, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced a license agreement to acquire the exclusive worldwide right
Source: www.prnewswire.com
Eli Lilly and Company announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation. The agreement includes an upfront payment of $47.5 million and potential development and regulatory milestones for up to $575 million. CNTX-0290, is a novel, small molecule somatostatin receptor type 4 (SSTR4) agonist that is currently being studied in Phase 1 clinical testing as a potential non-opioid treatment for chronic pain conditions.
